Oral and parenteral activity of 2,2'-anhydro-1- -D-arabinofuranosyl-5-fluorocytosine against both intraperitoneally and intracerebrally inoculated mouse leukemia.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001089:Arabinose / Q000008:administration & dosage / Q000627:therapeutic use; D002460:Cell Line; D005437:Flucytosine / Q000008:administration & dosage / Q000627:therapeutic use; D006824:Hybridization, Genetic; D007263:Infusions, Parenteral; D007274:Injections, Intraperitoneal; D007939:Leukemia L1210 / Q000188:drug therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D009705:Nucleosides / Q000008:administration & dosage / Q000627:therapeutic use*; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents; D009705:Nucleosides; D001089:Arabinose; D005437:Flucytosine